期刊文献+

人前列腺干细胞抗原的原核表达、纯化及鉴定 被引量:1

Prokaryotic expression,purification and identification of human prostate stem cell antigen
暂未订购
导出
摘要 目的构建包含人前列腺干细胞抗原(PSCA)的原核表达质粒,并进行诱导表达、蛋白纯化及鉴定。方法通过PCR扩增人PSCA基因片段,与过渡载体pGEM(-TEasy连接后进行测序鉴定,鉴定正确后,将PSCA基因片段酶切并插入含有谷胱甘肽s-转移本科GST标签的原核表达载体pET42a,得到重组质粒pET42a-PSCA。将pET42a-PSCA转化大肠埃希菌BL21(DE3),在IPTG诱导下表达GST-PSCA融合蛋白,用Glutathione-Sepharose4B柱对融合蛋白进行纯化,纯化产物进行SDS-PAGE及Western blotting鉴定。结果 PSCA基因的PCR产物大小与预期相符,测序结果与GenBank中的PSCA序列一致。pET42a-PSCA原核表达质粒构建正确,SDS-PAGE及Western blotting检测显示融合蛋白诱导表达成功,分子量大小约为43kD。结论成功构建了人PSCA的原核表达质粒,能在BL21菌株中表达,且纯化后得到较高纯度的GST-PSCA融合蛋白,为后续抗前列腺癌基因疫苗研究奠定了基础。 Objective To construct the prokaryotic expression plasmid of human prostate stem cell antigen (PSCA),to induce the expression of GST-PSCA fusion protein in E. coli BL21,and to identify the purified recombinant fusion protein. Methods The fragment of PSCA gene was amplified by PCR,and then cloned into the pGEM-T Easy vector. The transitional plasmid Teasy-PSCA was identified by DNA sequencing. The PSCA gene was digested from the plasmid Teasy-PSCA by restrictive enzyme BamH I and Sal I,and then inserted into the pET42a vector which contains a glutathione s-transterase (GST) tag. Following the double restriction enzyme digestion,the recombinant plasmid pET42a-PSCA was obtained and transformed into E. coli BL21 (DE3). The expression of GST-PSCA fusion protein was induced with IPTG. The recombinant fusion protein was purified by passing over a Glutathione Sepharose 4B column,and was identified by SDS-PAGE and Western blotting. Results The length of amplified PSCA gene fragment was consistent with that expected,and the sequence was correct as exemplified by the PSCA gene reported in GenBank. The result of enzyme digestion indicated that the prokaryotic expression plasmid pET42a-PSCA was successfully constructed. After transformation with pET42a-PSCA and induction with IPTG,the recombinant target protein of about 43kD was obtained. The GST-PSCA fusion protein was correctly identified by SDS-PAGE and Western blotting. Conclusions The prokaryotic expression plasmid of human PSCA gene has been successfully constructed. The GST-PSCA fusion protein may express and be purified in E. coli BL21,and it lays a foundation for further study on the anti-prostate cancer gene vaccine.
出处 《解放军医学杂志》 CAS CSCD 北大核心 2010年第8期986-988,共3页 Medical Journal of Chinese People's Liberation Army
基金 国家高技术研究发展计划(2006AA02A237,2007AA02Z451) 国家自然科学基金(30772002)
关键词 PSCA蛋白 质粒 重组融合蛋白质类 PSCA protein human plasmids recombinant fusion proteins
  • 相关文献

参考文献5

  • 1Reiter RE, Gu Z, Watabe T, etal. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer[J]. Proc Natl Acad Sci USA, 1998, 95(4): 1735-1740.
  • 2董金凯,阎瑾琦,高江平,韩刚,田仁礼,张亮,贾锐,于继云.人前列腺干细胞抗原基因PSCA的扩增及真核表达[J].军医进修学院学报,2009,30(1):79-81. 被引量:1
  • 3Garcia-Hemandez Mde L, Gray A, Hubby B, et al. Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity[J]. Cancer Res, 2008, 68(3): 861-869.
  • 4Ahmad S, Casey G, Sweeney P, et al. Prostate stem cell antigen DNA vacdnation breaks tolerance to self-antigen and inhibits prostate cancer growth[J]. Mol Ther, 2009, 17(6): 1101-1108.
  • 5韩刚,高江平,阎瑾琦,贾锐,张亮,董金凯,田仁礼,王晓雄,于继云.异种化PSCA融合基因抗前列腺癌DNA疫苗的构建及真核表达[J].军医进修学院学报,2009,30(1):88-90. 被引量:2

二级参考文献15

  • 1梁伟锋,张朝春,杨希才.一种多拷贝毕赤酵母表达载体的构建及人脑源性神经营养因子的表达[J].微生物学报,2005,45(1):34-38. 被引量:10
  • 2曹玉红,张光运,张国成,徐彦鸣,张建.人β防御素4基因的合成及克隆载体的构建[J].细胞与分子免疫学杂志,2007,23(4):377-378. 被引量:4
  • 3Dannull J, Diener PA, Prikler L, et al. Prosate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer[J]. Cancer Res, 2000, 60(19) :5522-5528.
  • 4Matsueda S, Kobayashi K, Nonaka Y, et al. Identification of new prostate stem cell antigen- derived peptides immunogenic in HLA- A2 + patients with hormone-refractory prostate cancer[ J]. Cancer immunol immunother, 2004, 53(6) :479489.
  • 5Kiessling A, SchmitzM, Stevanovic S, et al. Prostate stem cell antigen : identification of immunogenic peptides and assessment of reactive CD8 + T ceils in prostate cancer patients[ J]. Int J Cancer, 2002, 102(4) :390-397.
  • 6Matsueda S, Kobayashi K, Nonaka Y, et al. A prostate stem cell antigen-derived peptide immunogenic in HLA-A24 + prostate cancer patients[J]. Prostate, 2004, 60:205-213.
  • 7Zhang X, Yu C, Zhao J, et al. Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigenspecific CD8 + T-cell response and inhibits the PSCA + tumors growth in mice[J]. J Gene Med, 2007, 9(8) :715-726.
  • 8Munks MW, Mourich DV, Mittler RS, et al. 4-1BB and OX40 stimulation enhance CD8 and CD4 T-cell responses to a DNA prime, poxvirus boost vaccine [ J ]. Immunology, 2004, 112:559- 566.
  • 9Yang D, Holt GE, Velders MP, et al. Murine six-transmembrane epithelial antigen of the prostate, prostate stem cell antigen, and prostate-specific membrane antigen: prostate-specific cell-surface antigens highly expressed in prostate cancer of transgenic adenocarcinoma mouse prostate mice [ J]. Cancer Res, 2001, 61 ( 15 ) : 5857 -5860.
  • 10Nakamura K, Yasunaga Y, Ko D, et al. Cadmium-induced neoplastic transformation of human prostate epithelial cells [J ]. Int J Oncol, 2002, 20 (3) :543-547.

共引文献1

同被引文献12

  • 1Reiter RE,Gu Z,Watabe T. Prostate stem cell antigen:A cell surface marker overexpressed in prostate cancer[J].Proceedings of the National Academy of Sciences(USA),1998,(04):1735-1740.doi:10.1073/pnas.95.4.1735.
  • 2Tran CP,Lin C,Yamashiro J. Prostate stem cell antigen is a marker of late intermediate prostate epithelial cells[J].Molecular Cancer Research,2002,(02):113-121.
  • 3Sakamoto H,Yoshimura K,Saeki N. Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer[J].Nature Genetics,2008,(06):730-740.doi:10.1038/ng.152.
  • 4Saeki N,Gu J,Yoshida T. Prostate stem cell antigen:a Jekyll and Hyde molecule[J].Clinical Cancer Research,2010,(14):3533-3538.doi:10.1158/1078-0432.CCR-09-3169.
  • 5Hall SJ,Klotz L,Pantuck AJ. Integrated safety data from 4 randomized,double-blind,controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate Cancer[J].The Journal of Urology,2011,(03):877-881.doi:10.1016/j.juro.2011.04.070.
  • 6Fuessel S,Meye A,Schmitz M. Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells:results of a phase I clinical trial[J].Prostate,2006,(08):811-821.doi:10.1002/pros.20404.
  • 7Waeckerle-Men Y,Uetz-von Allmen E,Fopp M. Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma[J].Cancer Immunology Immunotherapy,2006,(12):1524-1533.doi:10.1007/s00262-006-0157-3.
  • 8Zhang X,Yu C,Zhao J. Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific CD8 + T-cell response and inhibits the PSCA +tumors growth in mice[J].Journal of Gene Medicine,2007,(08):715-726.doi:10.1002/jgm.1067.
  • 9Garcia-Hemandez Mde L,Gray A,Hubby B. Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity[J].Cancer Research,2008,(03):861-869.
  • 10Ahmad S,Casey G,Sweeney P. Prostate stem cell antigen DNA vaccination breaks tolerance to self-antigen and inhibits prostate cancer growth[J].Molecular Therapy,2009,(06):1101-1108.doi:10.1038/mt.2009.66.

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部